Glucose transporter-1 in pulmonary neuroendocrine carcinomas: Expression and survival analysis

Modern Pathology

Volumn 22, Issue 5, 2009, Pages 633-638

  Ozbudak, Irem H ^a   Shilo, Konstantin ^b   Tavora, Fabio ^b   Rassaei, Negar ^b   Chu, Wei Sing ^b   Fukuoka, Junya ^c   Jen, Jin ^d   Travis, William D ^e   Franks, Teri J ^b  

^a AKDENIZ UNIVERSITY   (Turkey)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^c TOYAMA UNIVERSITY HOSPITAL   (Japan)

^d NATIONAL CANCER INSTITUTE   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Carcinoid; GLUT 1; Lung; Neuroendocrine carcinoma; Survival

Indexed keywords

GLUCOSE TRANSPORTER 1;

ADULT; AGED; ARTICLE; BRONCHUS CARCINOID; CANCER STAGING; CANCER SURVIVAL; CARCINOID; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LARGE CELL CARCINOMA; LUNG CARCINOMA; MALE; NECROSIS; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR; SEX RATIO; SMALL CELL CARCINOMA; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NEUROENDOCRINE; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 67349233033     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.6     Document Type: Article

References (25)

1. Travis WD, Brambilla E, Muller-Hermelink HK, et al. Pathology & Genetics: Tumours of the Lung, Pleura, Thymus and Heart. WHO International Histological Classification of Tumours. IARC Press: Lyon, France, 2004.
2. Simon GR, Wagner H. Small cell lung cancer. Chest 2003;123(1 Suppl):259S-271S.
3. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005;202:654-662.
4. Behrooz A, Ismail-Beigi F. Stimulation of glucose transport by hypoxia: signals and mechanisms. News Physiol Sci 1999;14:105-110.
5. Godoy A, Ulloa V, Rodriguez F, et al. Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol 2006;207:614-627.
6. Younes M, Lechago LV, Somoano JR, et al. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res 1996;56:1164-1167.
7. Chung JK, Lee YJ, Kim SK, et al. Comparison of [18F]fluorodeoxyglucose uptake with glucose transporter- 1 expression and proliferation rate in human glioma and non-small-cell lung cancer. Nucl Med Commun 2004;25:11-17.
8. De SH, Landuyt W, Verbeken E, et al. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy± chemotherapy. BMC Cancer 2005;5:42.
9. Khandani AH, Whitney KD, Keller SM, et al. Sensitivity of FDG PET, GLUT1 expression and proliferative index in bronchioloalveolar lung cancer. Nucl Med Commun 2007;28:173-177.
10. Laudanski P, Koda M, Kozlowski L, et al. Expression of glucose transporter GLUT-1 and estrogen receptors ERalpha and ER-beta in human breast cancer. Neoplasma 2004;51:164-168.
11. Palit V, Phillips RM, Puri R, et al. Expression of HIF- 1alpha and Glut-1 in human bladder cancer. Oncol Rep 2005;14:909-913.
12. Wincewicz A, Sulkowska M, Koda M, et al. Clinicopathological significance and linkage of the distribution of HIF-1alpha and GLUT-1 in human primary colorectal cancer. Pathol Oncol Res 2007;13:15-20.
13. Younes M, Brown RW, Stephenson M, et al. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997;80:1046-1051.
14. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 1995;36:1625-1632.
15. Brown RS, Leung JY, Kison PV, et al. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 1999;40:556-565.
16. Fukuoka J, Dracheva T, Shih JH, et al. Desmoglein 3 as a prognostic factor in lung cancer. Hum Pathol 2007;38:276-283.
17. Airley R, Loncaster J, Davidson S, et al. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 2001;7:928-934.
18. Cantuaria G, Fagotti A, Ferrandina G, et al. GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer 2001;92:1144-1150.
19. Haber RS, Rathan A, Weiser KR, et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer 1998;83: 34-40.
20. Kang SS, Chun YK, Hur MH, et al. Clinical significance of glucose transporter 1 (GLUT1) expression in human breast carcinoma. Jpn J Cancer Res 2002;93:1123-1128.
21. Ito T, Noguchi Y, Satoh S, et al. Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. Mod Pathol 1998;11:437-443.
22. Pedersen MW, Holm S, Lund EL, et al. Coregulation of glucose uptake and vascular endothelial growth factor (VEGF) in two small-cell lung cancer sublines in vivo and in vitro. Neoplasia 2001;3:80-87.
23. Higashi K, Ueda Y, Sakurai A, et al. Correlation of Glut-1 glucose transporter expression with [18F]FDG uptake in non-small cell lung cancer. Eur J Nucl Med 2000;27:1778-1785.
24. Younes M, Brown RW, Mody DR, et al. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res 1995;15:2895-2898.
25. Mamede M, Higashi T, Kitaichi M, et al. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia 2005;7:369-379.